Watch our presentation @ the DIA 2020 Virtual Global Annual Meeting on June 18
Not only are clinical trials expensive, they also have high failure rates. This is ultimately due to our inability to select the right subjects and detect biological indicators early enough, before the time, cost, and scale escalate further. Clinically-relevant biomarkers hold the promise to turn this around, enabling more sensitive and quicker demonstration of selection, efficacy, and safety.
Finding such biomarkers is now at our fingertips, as multi-omics views of potential/target subjects are becoming increasingly available. However, despite the growing volume of data, successfully discovering and applying such biomarkers in clinical development remains a missed opportunity.
In this talk at the DIA 2020 Virtual Global Annual Meeting on June, 18, our CEO Misha Kapushesky will:
- Explore why cross-trials and Life Science Data/metadata management strategy is a prerequisite for finding robust and predictive omics biomarkers.
- Draw upon our industry experience to highlight best practices and proven solutions for making omics and clinical data FAIR and how this has a bearing on protocol design, patient selection, and integrative cross-study meta-analysis.
JOIN US @ DIA 2020 VIRTUAL!
Date — June 18, 2020, 5pm EDT
Track — Clinical Trials & Clinical Operations
Session — Bridging bench to bedside with novel biomarkers